These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 31008931)

  • 41. Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
    Raphael J; Vincent M; Boldt G; Shah PS; Rodrigues G; Blanchette P
    Am J Clin Oncol; 2019 May; 42(5):440-445. PubMed ID: 30913091
    [TBL] [Abstract][Full Text] [Related]  

  • 42. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-Analysis.
    Hu M; Hu Y; He J; Li B
    PLoS One; 2016; 11(1):e0147374. PubMed ID: 26824699
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.
    Dong ZY; Zhai HR; Hou QY; Su J; Liu SY; Yan HH; Li YS; Chen ZY; Zhong WZ; Wu YL
    Oncologist; 2017 Jan; 22(1):61-69. PubMed ID: 28126915
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutrophil-Lymphocyte Ratio as a Prognostic Parameter in NSCLC Patients Receiving EGFR-TKIs: A Systematic Review and Meta-Analysis.
    Tang M; Gao X; Sun H; Tian S; Dong J; Liu Z; Liu W
    J Oncol; 2021; 2021():6688346. PubMed ID: 33542732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis.
    Su W; Zhang X; Cai X; Peng M; Wang F; Wang Y
    Medicine (Baltimore); 2019 Mar; 98(10):e14568. PubMed ID: 30855441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y; Liu W; Zhang N; Yang X; Li J; Long S
    Cancer Med; 2021 Oct; 10(20):7021-7039. PubMed ID: 34423578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.
    Lee KW; Lee SS; Kim SB; Sohn BH; Lee HS; Jang HJ; Park YY; Kopetz S; Kim SS; Oh SC; Lee JS
    Clin Cancer Res; 2015 Jan; 21(2):357-64. PubMed ID: 25388162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Glasgow prognostic score predicts efficacy and prognosis in patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment.
    Kasahara N; Imai H; Naruse I; Tsukagoshi Y; Kotake M; Sunaga N; Kaira K; Maeno T; Asao T; Hisada T
    Thorac Cancer; 2020 Aug; 11(8):2188-2195. PubMed ID: 32495520
    [TBL] [Abstract][Full Text] [Related]  

  • 52. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
    An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
    Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Loss of MiR-424-3p, not miR-424-5p, confers chemoresistance through targeting YAP1 in non-small cell lung cancer.
    Zhang M; Zeng J; Zhao Z; Liu Z
    Mol Carcinog; 2017 Mar; 56(3):821-832. PubMed ID: 27500472
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Mao C; Yuan JQ; Yang ZY; Fu XH; Wu XY; Tang JL
    Medicine (Baltimore); 2015 May; 94(21):e775. PubMed ID: 26020382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
    Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
    Front Oncol; 2022; 12():962173. PubMed ID: 36059629
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer.
    Wang C; Yu X; Wang W
    Medicine (Baltimore); 2016 Dec; 95(52):e5539. PubMed ID: 28033249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.
    Ai B; Liu H; Huang Y; Peng P
    Oncotarget; 2016 Jul; 7(28):44583-44595. PubMed ID: 27323821
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic value of consolidation-to-tumor ratio on computed tomography in NSCLC: a meta-analysis.
    Wu Y; Song W; Wang D; Chang J; Wang Y; Tian J; Zhou S; Dong Y; Zhou J; Li J; Zhao Z; Che G
    World J Surg Oncol; 2023 Jun; 21(1):190. PubMed ID: 37349739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.